MDxHealth Licenses Methylation Technology to Takara | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today said that it has licensed to Takara Bio non-exclusive worldwide rights to its methylation-specific PCR technology.

Japan-based Takara has licensed the technology for the scientific research market. In exchange, MDxHealth will receive an upfront fee and royalties on sales of products incorporating the MSP technology. The firms did not disclose additional terms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.